World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
43075
World Ranking
10701
National Ranking
582

Richard F. Schlenk publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard F. Schlenk sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 621 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard F. Schlenk D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard F. Schlenk sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard F. Schlenk is affiliated with the University Hospital Heidelberg in Germany. Their research primarily spans medicine, with a strong focus on hematology and molecular biology.

The main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Key subfields of their research cover:

  • Hematology
  • Molecular Biology
  • Genetics
  • Oncology
  • Public Health, Environmental and Occupational Health

They have contributed extensively to several topics, notably:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Cancer Genomics and Diagnostics
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments

Frequent publication venues for their work include:

  • Blood
  • Haematologica
  • Annals of Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Leukemia

Notable recent papers authored or coauthored by Richard F. Schlenk span various aspects of leukemia and cancer genomics, as listed below:

  • Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial, 2023, The Lancet
  • Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers, 2021, Cancer Discovery
  • NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents, 2020, Annals of Oncology
  • Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin, 2021, Blood
  • The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology, 2022, Nature Cancer

Richard F. Schlenk has close collaborative ties with several coauthors, including:

  • Carsten Müller-Tidow
  • Mark J. Levis
  • Stefan Fröhling
  • Pau Montesinos
  • Alexander E. Perl

Best Publications

  • Genomic Classification and Prognosis in Acute Myeloid Leukemia

    Elli Papaemmanuil;Moritz Gerstung;Lars Bullinger;Verena I Gaidzik

  • Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

    Richard F. Schlenk;Konstanze Döhner;Jürgen Krauter;Stefan Fröhling

  • Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

    Richard M. Stone;Sumithra J. Mandrekar;Ben L. Sanford;Kristina Laumann

  • Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

    F. Lo-Coco;G. Avvisati;M. Vignetti;C. Thiede

  • Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.

    Lars Bullinger;Konstanze Döhner;Eric Bair;Stefan Fröhling

  • Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

    Stefan Fröhling;Richard F. Schlenk;Jochen Breitruck;Axel Benner

  • Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

    John Koreth;Richard Schlenk;Kenneth J. Kopecky;Sumihisa Honda

  • Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

    Konstanze Döhner;Richard F Schlenk;Marianne Habdank;Claudia Scholl

  • IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

    Peter Paschka;Richard F. Schlenk;Verena I. Gaidzik;Marianne Habdank

  • p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

    Hartmut Döhner;Konstanze Fischer;Martin Bentz;Katrin Hansen

  • Targeting FLT3 mutations in AML: review of current knowledge and evidence.

    Naval Daver;Richard F. Schlenk;Nigel H. Russell;Mark J. Levis

  • TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.

    Frank G. Rücker;Richard F. Schlenk;Lars Bullinger;Sabine Kayser

  • CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations

    Stefan Fröhling;Richard F. Schlenk;Ina Stolze;Jörg Bihlmayr

  • The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.

    Sabine Kayser;Konstanze Döhner;Jürgen Krauter;Claus Henning Köhne

  • Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

    Erdogan Taskesen;Lars Bullinger;Andrea Corbacioglu;Mathijs A. Sanders

  • Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup

    RF Schlenk;A Benner;J Krauter;T Buchner

  • Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

    Jan Krönke;Richard F. Schlenk;Kai-Ole Jensen;Florian Tschürtz

  • Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the Acute Myeloid Leukemia Study Group Ulm

    Konstanze Döhner;Karen Tobis;Regina Ulrich;Stefan Fröhling

  • Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

    Richard F Schlenk;Sabine Kayser;Lars Bullinger;Guido Kobbe

  • The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

    Jan J. Cornelissen;Alois Gratwohl;Richard F. Schlenk;Jorge Sierra

Frequent Co-Authors

Hartmut Döhner
Hartmut Döhner University of Ulm
Konstanze Döhner
Konstanze Döhner University of Ulm
Arnold Ganser
Arnold Ganser Hannover Medical School
Lars Bullinger
Lars Bullinger Charité - University Medicine Berlin
Michael Lübbert
Michael Lübbert University of Freiburg
Michael Heuser
Michael Heuser Hannover Medical School
Axel Benner
Axel Benner German Cancer Research Center
Brigitte Schlegelberger
Brigitte Schlegelberger Hannover Medical School
Ulrich Germing
Ulrich Germing Heinrich Heine University Düsseldorf
Gudrun Göhring
Gudrun Göhring Hannover Medical School

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students exploring alternatives to traditional medical school, a variety of online healthcare degrees can offer rewarding career paths with greater flexibility and accessibility. Many choose to pursue nursing due to high demand and the many educational options. Programs like the easiest rn program can be a great entry point for those looking for less competitive admissions requirements and a clear pathway to a registered nursing license.

If you’re interested in a healthcare career outside of direct patient care, consider enrolling in online medical coding classes with financial aid. These programs prepare you for essential roles in healthcare information management, often with the flexibility and affordability many students need.

For prospective nurses concerned about entrance exams, look for nursing schools that don't require teas or HESI exams. This option can simplify the application process and make nursing education more accessible.

Additionally, an online healthcare administration degree can lead to leadership roles in hospitals, clinics, or other medical settings. These accelerated programs are ideal for working adults or career-changers seeking advancement in the healthcare sector.

Best Scientists Citing Richard F. Schlenk

Trending Scientists

Recently Published Articles